IL6 and colonic neoplasm: We concluded from these data that in colon cancer, IL-6 trans-signaling apparently acted downstream of the EGF-R and blockade of IL-6 trans-signaling might represent a novel therapeutic window for patients resistant to anti-EGF-R antibodies (Figure 3) [146].